Multiple sclerosis future or investigational therapies
Jump to navigation
Jump to search
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis future or investigational therapies |
|
FDA on Multiple sclerosis future or investigational therapies |
|
CDC on Multiple sclerosis future or investigational therapies |
|
Multiple sclerosis future or investigational therapies in the news |
|
Blogs on Multiple sclerosis future or investigational therapies |
|
Risk calculators and risk factors for Multiple sclerosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Future or Investigational Therapies
Therapies under investigation:
- Combination of MS drugs: Combination of mitoxantrone and glatiramer acetate.[1]
- Drugs that are used in other diseases: alemtuzumab[2], daclizumab [3], inosine[4], BG00012[5], fingolimod[6] and teriflunomide.
- Drugs designed specifically for MS: laquinimod[7] and Neurovax.[8]
- Others: Low dose naltrexone is used for some autoimmune diseases such as multiple sclerosis.[9][10]
References
- ↑ United Kingdom early Mitoxantrone Copaxone trial. Onyx Healthcare (2006-01-01). Retrieved on 2007-09-02.
- ↑ Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN. Genzyme (2007-02-01). Retrieved on 2007-09-02.
- ↑ Daclizumab. PDL Biopharma (2006-01-01). Retrieved on 2007-09-02.
- ↑ Treatment of Multiple Sclerosis Using Over the Counter Inosine. ClinicalTrials.gov (2006-03-16). Retrieved on 2007-09-02.
- ↑ Efficacy and Safety of BG00012 in Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov (2007-09-01). Retrieved on 2007-11-12.
- ↑ Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov (2006-02-09). Retrieved on 2007-09-02.
- ↑ Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T (2005). "Treatment with laquinimod reduces development of active MRI lesions in relapsing MS". Neurology. 64 (6): 987–91. doi:10.1212/01.WNL.0000154520.48391.69. PMID 15781813.
- ↑ Darlington CL (2005). "Technology evaluation: NeuroVax, Immune Response Corp". Curr. Opin. Mol. Ther. 7 (6): 598–603. PMID 16370383.
- ↑ Agrawal YP (2005). "Low dose naltrexone therapy in multiple sclerosis". Med. Hypotheses. 64 (4): 721–4. doi:10.1016/j.mehy.2004.09.024. PMID 15694688.
- ↑ search of clinicaltrials.gov data-base for Low dose naltrexone Multiple Sclerosis